Reporter Bioassays

The VEGF Bioassay is a bioluminescent cell-based assay that measures VEGF stimulation and inhibition of KDR (VEGFR-2) using NFAT-RE as a readout. T...

The VEGF Bioassay is a bioluminescent cell-based assay that measures VEGF stimulation and inhibition of KDR (VEGFR-2) using NFAT-RE as a readout. T...

The VEGF Bioassay is a bioluminescent cell-based assay that measures VEGF stimulation and inhibition of KDR (VEGFR-2) using NFAT-RE as a readout. T...

TIM-3 (CD366, HAVCR2) is an immune checkpoint receptor expressed on a subset of activated T cells, regulatory T cells (Tregs), macrophages and dend...

TIM-3 (CD366, HAVCR2) is an immune checkpoint receptor expressed on a subset of activated T cells, regulatory T cells (Tregs), macrophages and dend...

TIM-3 (CD366, HAVCR2) is an immune checkpoint receptor expressed on a subset of activated T cells, regulatory T cells (Tregs), macrophages and dend...

TIGIT is an immune checkpoint protein expressed on lymphocytes. Highest expression levels are observed on CD4+ and CD8+ T cells, regulatory T cells...

Measure potency and stability of biologics designed to block the TIGIT/CD155 interaction.

TIGIT is an immune checkpoint protein expressed on lymphocytes. Highest expression levels are observed on CD4+ and CD8+ T cells, regulatory T cells...

TIGIT Negative Cells are control cells for use with the TIGIT/CD155 Blockade Bioassay.

LAG-3 is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells, and plays a critical role in reg...

Immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of...

The T Cell Activation Bioassay, Propagation Model, provides a biologically relevant and specific MOA-based measure of TCR/CD3 Effector Cells withou...

Immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of...

The T Cell Activation Bioassay, Propagation Model, provides a biologically relevant and specific MOA-based measure of TCR/CD3 Effector Cells withou...

Immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of...

Immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of...

Recombinant VEGF may be used as a positive control ligand in the VEGF Bioassay (Cat.# GA2001, GA2005). Human VEGF-165, amino acids Ala27-Arg191 (Ac...

Receptor activator of nuclear factor-κB (NF-κB; RANK/TRANCE receptor/TNFRSF11A) is a member of the tumor necrosis factor receptor (TNFR) family. Bi...

Receptor activator of nuclear factor-κB (NF-κB; RANK/TRANCE receptor/TNFRSF11A) is a member of the tumor necrosis factor receptor (TNFR) family. Bi...

Receptor activator of nuclear factor-κB (NF-κB; RANK/TRANCE receptor/TNFRSF11A) is a member of the tumor necrosis factor receptor (TNFR) family. Bi...

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor ...

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor ...

PD-1+TIGIT Combination Bioassay, Propagation Model, is a biologically relevant MOA-based assay that can be used to measure potency and stability o...

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor ...

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor ...

PD-1 is an immune inhibitory receptor expressed on activated T cells and B cells and plays a critical role in regulating immune responses to tumor ...

PD-1, also known as CD279, is an immune checkpoint receptor expressed on T and B lymphocytes following activation. Engagement of PD-1 by either of ...

PD-1, also known as CD279, is an immune checkpoint receptor expressed on T and B lymphocytes following activation. Engagement of PD-1 by either of ...

The OX40 Bioassay, (Cat.# J2172), is a bioluminescent cell-based assay that can be used to measure the potency and stability of ligands or agonist ...

The OX40 Bioassay, (Cat.# J2172), is a bioluminescent cell-based assay that can be used to measure the potency and stability of ligands or agonist ...

The OX40 Bioassay, (Cat.# J2172), is a bioluminescent cell-based assay that can be used to measure the potency and stability of ligands or agonist ...

Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) of antibodies that target virus-infected or diseased...

Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) of antibodies that target virus-infected or diseased...

Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) of antibodies that target virus-infected or diseased...

Fc receptor-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) by which antibodies target dise...

LAG-3 is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells, and plays a critical role in reg...

LAG-3 is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells, and plays a critical role in reg...

LAG-3 is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells, and plays a critical role in reg...

Interleukin-6 (IL-6, originally termed BCDF/BSF2) was first identified in 1983 alongside molecules with similar but distinct functional properties ...

Interleukin-6 (IL-6, originally termed BCDF/BSF2) was first identified in 1983 alongside molecules with similar but distinct functional properties ...

Interleukin-6 (IL-6, originally termed BCDF/BSF2) was first identified in 1983 alongside molecules with similar but distinct functional properties ...

Interleukin-23 (IL-23) was first described in 2000 when a computational screen identified a novel sequence (p19) that combined with the p40 subunit...

Interleukin-23 (IL-23) was first described in 2000 when a computational screen identified a novel sequence (p19) that combined with the p40 subunit...

Interleukin-23 (IL-23) was first described in 2000 when a computational screen identified a novel sequence (p19) that combined with the p40 subunit...

The IL-2 Bioassay is a bioluminescent cell-based assay designed to measure IL-2 stimulation or inhibition. The IL-2 Bioassay Cells are provided in ...

The IL-2 Bioassay is a bioluminescent cell-based assay designed to measure IL-2 stimulation or inhibition. The IL-2 Bioassay Cells are provided in ...

The IL-2 Bioassay is a bioluminescent cell-based assay designed to measure IL-2 stimulation or inhibition. The IL-2 Bioassay Cells are provided in ...